Standout Papers

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study 2010 2026 2015 2020 802
  1. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study (2010)
    Howard I. Scher, Tomasz M. Beer et al. The Lancet

Immediate Impact

5 from Science/Nature 72 standout
Sub-graph 1 of 18

Citing Papers

Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones
2023 Standout
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
2023 Standout
3 intermediate papers

Works of Julia Shelkey being referenced

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
2010 Standout

Author Peers

Author Last Decade Papers Cites
Julia Shelkey 812 245 301 9 946
Nikhil Babu Oommen 893 211 360 7 1.1k
Youyi Shu 791 251 276 13 991
Emilda Thompson 650 163 220 7 754
S. Polyakov 774 263 263 18 894
Mary Barrett 580 158 221 6 903
Murilo Luz 897 290 300 30 991
Mari Nakazawa 824 187 425 23 993
Eren Demirhan 657 211 224 15 924
Carl Le 727 176 366 10 1.1k
Alison Reid 729 142 398 19 1.1k

All Works

Loading papers...

Rankless by CCL
2026